Skip to main content
. 2023 Mar 11;15(6):1369. doi: 10.3390/nu15061369

Table 3.

Associations between quality-of-life functions and MAG-EPA intervention, per-protocol analysis.

Variables Placebo MAG-EPA Difference between Group
Mean (SE) MD (95% CI) p-Value * Mean (SE) MD (95% CI) p-Value * MD (95% CI) p-Value **
EPIC-26      
Urinary Incontinence            
  Randomization 94.5 (2.0) 0.0    94.2 (1.9) 0.0         
  3 Months Post-RP 47.3 (3.7) −47.2 (−55.3; −39.2) <0.0001 37.1 (3.8) −57.2 (−65.3; −48.9) <0.0001 −7.2 (−17.9; 3.4) 0.18
  6 Months Post-RP 66.4 (4.1) −28.1 (−36.9; −19.3) <0.0001 58.3 (4.3) −35.9 (−45.2; −26.7) <0.0001 −4.7 (−16.5; 7.2) 0.44
  9 Months Post-RP 70.8 (3.8) −23.7 (−31.6; −15.7) <0.0001 65.7 (4.1) −28.5 (−37.1; −19.9) <0.0001 −1.4 (−12.6; 9.7) 0.80
  12 Months Post-RP 74.4 (3.9) −19.1 (−28.0; −12.1) <0.0001 65.8 (4.1) −28.6 (−37.1; −20.2) <0.0001 −4.4 (−15.9; 7.2) 0.45
Urinary irritation                        
  Randomization 85.2 (2.1) 0.0    82.5 (2.0) 0.0         
  3 Months Post-RP 78.9 (2.3) −6.3 (−11.4; −1.3) 0.01 77.0 (2.3) −5.4 (−10.5; −0.3) 0.04 0.3 (−5.9; 6.4) 0.93
  6 Months Post-RP 85.1 (2.0) −0.1 (−4.5; 4.3) 0.95 85.8 (2.0) 3.3 (−1.2; 7.7) 0.15 2.1 (−2.9; 7.0) 0.41
  9 Months Post-RP 87.5 (1.9) 2.3 (−1.3; 6.0) 0.21 85.3 (1.9) 2.9 (−0.8; 6.5) 0.12 0.7 (−3.8; 5.1) 0.77
  12 Months Post-RP 84.4 (2.0) −0.8 (−5.0; 3.5) 0.72 87.3 (2.0) 4.9 (0.6; 9.2) 0.03 5.5 (0.4; 10.6) 0.03
Sexual function                        
  Randomization 66.3 (3.6) 0.0    63.2 (3.5) 0.0         
  3 Months Post-RP 19.0 (3.0) −47.3 (−54.6; −40.0) <0.0001 18.8 (3.0) −44.4 (−51.7; −37.1) <0.0001 −0.7 (−8.5; 7.1) 0.86
  6 Months Post-RP 28.1 (3.6) −38.2 (−45.8; −30.6) <0.0001 27.4 (3.8) −35.8 (−43.6; −28.0) <0.0001 −1.2 (−10.6; 8.2) 0.80
  9 Months Post-RP 33.0 (3.8) −33.3 (−40.8; −25.8) <0.0001 31.4 (4.0) −31.8 (−39.6; −24.1) <0.0001 −2.3 (−12.2; 7.6) 0.65
  12 Months Post-RP 36.2 (4.3) −30.1 (−38.1; −22.2) <0.0001 32.4 (4.5) −30.8 (−39.0; −22.6) <0.0001 −3.8 (−15.1; 7.5) 0.50
Bowel function                        
  Randomization 93.1 (1.7) 0.0    90.3 (1.6) 0.0         
  3 Months Post-RP 92.8 (1.8) −0.3 (−4.3; 3.7) 0.86 88.5 (1.8) −1.8 (−5.8; 2.2) 0.38 −3.2 (−8.2; 1.7) 0.20
  6 Months Post-RP 93.6 (1.4) 0.5 (−2.6; 3.7) 0.75 91.5 (1.4) 1.2 (−1.9; 4.5) 0.45 −1.6 (−5.2; 2.0) 0.37
  9 Months Post-RP 94.3 (1.7) 1.2 (−2.8; 5.2) 0.56 89.9 (1.8) −0.4 (−4.5; 3.7) 0.85 −2.4 (−6.8; 2.0) 0.28
  12 Months Post-RP 96.2 (1.3) 3.0 (−0.3; 6.4) 0.07 93.9 (1.3) 3.6 (0.3; 6.9) 0.03 −1.0 (−4.4; 2.4) 0.55
Hormonal function                        
  Randomization 86.3 (2.0) 0.0    87.9 (1.9) 0.0         
  3 Months Post-RP 88.0 (1.9) 1.6 (−1.4; 4.6) 0.29 87.2 (1.9) −0.7 (−3.8; 2.4) 0.64 −1.2 (−5.2; 2.9) 0.57
  6 Months Post-RP 88.7 (1.5) 2.4 (−0.3; 5.1) 0.08 89.2 (1.6) 1.3 (−1.4; 3.9) 0.35 −0.2 (−3.2; 2.8) 0.90
  9 Months Post-RP 87.8 (1.6) 1.4 (−1.8; 4.6) 0.38 88.6 (1.7) 0.7 (−2.5; 3.9) 0.66 0.5 (−3.3; 4.3) 0.80
  12 Months Post-RP 88.3 (1.7) 1.9 (−1.3; 5.1) 0.24 90.4 (1.7) 2.5 (−0.7; 5.7) 0.12 1.7 (−2.2; 5.6) 0.38
IPSS         
Voiding and storage Problem                        
Randomization 9.1 (0.9) 0.0    9.0 (0.9) 0.0         
3 Months Post-RP 11.1 (1.0) 1.9 (−0.3; 4.2) 0.08 11.1 (1.0) 2.2 (−0.1; 4.4) 0.06 −0.3 (−2.9; 2.4) 0.85
6 Months Post-RP 7.8 (0.7) −1.3 (−3.0; 0.5) 0.15 8.4 (0.8) −0.6 (−2.4; 1.1) 0.48 0.2 (−1.6; 2.0) 0.81
9 Months Post-RP 7.0 (0.7) −2.2 (−3.8; −0.5) 0.009 7.2 (0.8) −1.8 (−3.5; −0.2) 0.03 −0.1 (−1.9; 1.7) 0.91
12 Months Post-RP 7.0 (0.7) −2.1 (−3.8; −0.5) 0.01 6.4 (0.7) −2.6 (−4.2; −0.9) 0.002 −0.9 (−2.8; 0.9) 0.30

Notes: MAG-EPA: monoacylglyceride-conjugated eicosapentaenoic acid; RP: radical prostatectomy. * p-value were obtained using mixed models adjusted for age. BMI and NCCN risk; ** p-value were obtained by mixed models adjusted for age, BMI, NCCN risk, and baseline score.